U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223034) titled 'A Study of 177Lu-PSMA-617 in People With Gliomas' on Oct. 28.
Brief Summary: The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Study Start Date: Oct. 27
Study Type: INTERVENTIONAL
Condition:
Glioma
Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
Glioblastoma, IDH-wildtype
Diffuse Midline Glioma, H3 K27-Altered
Diffuse Hemispheric Glioma, H3 G34-mutant
Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
Intervention:
DRUG: Temozolomide
Patients will begin taking Temozolomide orally on the first ...